These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 24117412

  • 21. Combined therapy: photodynamic therapy and bevacizumab to treat myopic neovascular membranes. One-year follow-up.
    Desco MC, Mataix J, Garcia-Pous M, Palacios-Pozo E, Navea A.
    Retina; 2011 Mar; 31(3):475-81. PubMed ID: 20966825
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial.
    Ahmadieh H, Taei R, Riazi-Esfahani M, Piri N, Homayouni M, Daftarian N, Yaseri M.
    Retina; 2011 Oct; 31(9):1819-26. PubMed ID: 21555967
    [Abstract] [Full Text] [Related]

  • 24. Intravitreal ranibizumab and bevacizumab in combination with full-fluence verteporfin therapy and dexamethasone for exudative age-related macular degeneration.
    Forte R, Bonavolontà P, Benayoun Y, Adenis JP, Robert PY.
    Ophthalmic Res; 2011 Oct; 45(3):129-34. PubMed ID: 20847575
    [Abstract] [Full Text] [Related]

  • 25. Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration.
    Aggio FB, Melo GB, Höfling-Lima AL, Eid Farah M.
    Acta Ophthalmol Scand; 2006 Dec; 84(6):831-3. PubMed ID: 17083553
    [No Abstract] [Full Text] [Related]

  • 26. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia.
    Parodi MB, Iacono P, Papayannis A, Sheth S, Bandello F.
    Arch Ophthalmol; 2010 Apr; 128(4):437-42. PubMed ID: 20142520
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab.
    Montero JA, Ruiz-Moreno JM, Sanchis-Merino E, Perez-Martin S.
    Retina; 2013 Mar; 33(3):508-12. PubMed ID: 23099497
    [Abstract] [Full Text] [Related]

  • 29. One-year follow-up of combined customized therapy. Photodynamic therapy and bevacizumab for exudative age-related macular degeneration.
    Navea A, Mataix J, Desco MC, Garcia-Pous M, Palacios E.
    Retina; 2009 Jan; 29(1):13-9. PubMed ID: 18854782
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Efficacy of combined photodynamic therapy and intravitreal bevacizumab injection versus photodynamic therapy alone in polypoidal choroidal vasculopathy.
    Kim SJ, Yu HG.
    Retina; 2011 Oct; 31(9):1827-34. PubMed ID: 21734621
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Effects of combination therapy with verteporfin photodynamic therapy and ranibizumab in patients with age-related macular degeneration.
    Wolf-Schnurrbusch UE, Brinkmann CK, Berger L, Wolf S.
    Acta Ophthalmol; 2011 Sep; 89(6):585-90. PubMed ID: 19878113
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.